Dual-Targeted Alpha Therapy Mitigates Prostate Cancer and Boosts Immune Checkpoint Blockade Therapy

By
Jamie Kang
-
0
11
Investigators reported on Sigma-1 receptor and PSMA dual-specific peptide with efficient 225‑actinium labeling for targeted alpha therapy and alpha-immunotherapy of murine prostate tumors.
[Journal of Controlled Release]
Abstract